Centers for Medicare and Medicaid Services (CMS) is issuing this memorandum to provide clarifying guidance to Medicare Part D plan sponsors concerning the Part D program’s any willing pharmacy (AWP) requirement.
On August 22, 2014, the DEA issued a final rule (79 FR 49661) in which they rescheduled hydrocodone combination products (HCPs) from schedule III to schedule II of the Controlled Substances Act as of October 6, 2014.